₹ 1.5 Cr
Volume transacted
108.0 K
stocks traded
Last Updated time: 26 Jul 9.00 AM
Suven Life Sciences Ltd
NSE: SUVEN
PE
0
Last updated : 26 Jul 9.00 AM
The P/E Ratio of Suven Life Sciences Ltd is 0 as of 26 Jul 9.00 AM .a1#The P/E Ratio of Suven Life Sciences Ltd changed from 0 on March 2019 to 0 on March 2024 . This represents a CAGR of 0.0% over 6 years. a1#The Latest Trading Price of Suven Life Sciences Ltd is ₹ 141.2 as of 25 Jul 15:30 .a1#The PE Ratio of Pharmaceuticals Industry has changed from 28.3 to 27.2 in 5 years. This represents a CAGR of -0.79%a1# The PE Ratio of Automobile industry is 18.9. The PE Ratio of Finance industry is 23.0. The PE Ratio of IT - Software industry is 29.1. The PE Ratio of Pharmaceuticals industry is 38.6. The PE Ratio of Retail industry is 143.1. The PE Ratio of Textiles industry is 24.3. In 2024a1#The Market Cap of Suven Life Sciences Ltd changed from ₹ 3320 crore on March 2019 to ₹ 2174 crore on March 2024 . This represents a CAGR of -6.82% over 6 years. a1#The Revenue of Suven Life Sciences Ltd changed from ₹ 9.98 crore to ₹ 6.67 crore over 8 quarters. This represents a CAGR of -18.25% a1#The EBITDA of Suven Life Sciences Ltd changed from ₹ -14.64 crore to ₹ -26 crore over 8 quarters. This represents a CAGR of 33.27% a1#The Net Pr of Suven Life Sciences Ltd changed from ₹ -16.33 crore to ₹ -26.54 crore over 8 quarters. This represents a CAGR of 27.48% a1#The Dividend Payout of Suven Life Sciences Ltd changed from 48.72 % on March 2019 to 0 % on March 2024 . This represents a CAGR of -100.00% over 6 years. a1#
Open Demat Account
Enter your mobile no. to continue
+91
*By signing up you agree to our terms & conditions
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share. P/E Ratio Formula P/E ratio = (CMP of share/ Earning per share) Types of Price to Earning Ratio 1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance. 2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.
Period | |
---|---|
Mar '19 | 0 |
Mar '20 | 0 |
Mar '21 | 0 |
Mar '22 | 0 |
Mar '23 | 0 |
Mar '24 | 0 |
Market Cap
₹ 3,079 Cr
EPS
₹ 0.0
P/E Ratio (TTM) *
0.0
P/B Ratio (TTM) *
11.4
Day’s High
₹ 141.2
Day’s Low
₹ 133.05
DTE *
0.0
ROE *
-38.9
52 Week High
₹ 145.0
52 Week Low
₹ 60.96
ROCE *
-39.1
* All values are consolidated
Last Updated time: 26 Jul 9.00 AM
* All values are consolidated
Last Updated time: 26 Jul 9.00 AM
Suven Life Sciences Ltd
NSE: SUVEN
PRICE
₹ 141.2
6.70 (4.98%)
Last updated : 25 Jul 15:30
The current market price or CMP refers to the price at which the securities are trading in the share market. Current price in Over-the-counter costs: The following current price depends upon the bid price & the asking price when a financial asset is sold over-the-counter(OTC). Current Price in Bond Market: The current price of a bond is determined by measuring the actual interest rate against the bid-related interest rate. The par or the face value is then calculated to represent the remaining interest payments due which occur before the maturity of the bond.
1M
1Y
3Y
5Y
* All values are in Rupees
Strength
3
S
Weakness
2
W
Opportunity
0
O
Threats
1
T
Market Value
₹ 3,079
Asset Value
₹ 181
16.0 X
Value addition
* All values are in Rupees
Company Name | PE | Market Cap (INR Cr.) |
---|---|---|
Suven Life Sciences Ltd | 0 | 3,079 |
Sun Pharmaceuticals Industries Ltd | 40 | 399,537 |
Zydus Lifesciences Ltd | 31 | 121,312 |
Cipla Ltd | 28 | 121,120 |
Divis Laboratories Ltd | 75 | 120,782 |
Dr Reddys Laboratories Ltd | 20 | 114,348 |
Earnings
₹-105 Cr
0.0 X
PE Ratio
Market Cap
₹3079Cr
PE Ratio
PS Ratio
PB Ratio
The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.
P/E ratio = (CMP of share/ Earning per share)
1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.
Earnings
₹-105 Cr
0.0 X
PE Ratio
Market Cap
₹3079Cr
PE Ratio
PS Ratio
PB Ratio
The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.
P/E ratio = (CMP of share/ Earning per share)
1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.
Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore
Period | |
---|---|
Mar '19 | 3321 |
Mar '20 | 272 |
Mar '21 | 896 |
Mar '22 | 1348 |
Mar '23 | 1057 |
Mar '24 | 2174 |
* All values are a in ₹crore
Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services. Types of Revenue: 1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered. 2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees. Formula for Revenue: The formula for calculating revenue is based on two goods & services: For goods: Revenue = Avg unit price x Number of Units sold For services: Revenue = Avg unit price x Number of Customers served.
Period | |
---|---|
Jun '22 | 10 |
Sep '22 | 5 |
Dec '22 | 5 |
Mar '23 | 8 |
Jun '23 | 9 |
Sep '23 | 16 |
Dec '23 | 9 |
Mar '24 | 7 |
* All values are a in ₹crore
PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.
Period | |
---|---|
Jun '22 | -15 |
Sep '22 | -21 |
Dec '22 | -49 |
Mar '23 | -26 |
Jun '23 | -22 |
Sep '23 | -11 |
Dec '23 | -40 |
Mar '24 | -26 |
* All values are a in ₹crore
Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions. Net Profit formula is expressed as: Net Profit = Total Revenue - Total Expense Net Profit Margin Ratio: Net Profit Margin Ratio = Net Profit / Total Revenue
Period | |
---|---|
Jun '22 | -16 |
Sep '22 | -23 |
Dec '22 | -51 |
Mar '23 | -28 |
Jun '23 | -24 |
Sep '23 | -13 |
Dec '23 | -42 |
Mar '24 | -27 |
* All values are a in ₹crore
Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.
Period | |
---|---|
Mar '19 | 49 |
Mar '20 | 0 |
Mar '21 | 0 |
Mar '22 | 0 |
Mar '23 | 0 |
Mar '24 | 0 |
* All values are a in %
Suven Life Sciences Limited (Formerly known as Suven Pharmaceuticals Ltd) was incorporated in March, 1989. The Company changed its name from Suven Pharmaceuticals Limited to Suven Life Sciences Limited in September, 2003. Promoted by Sudharani Jasti and Venkateswarlu Jasti, the Company began operations in 1989 as specialty chemicals provider. The Company is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. Suven has a wholly owned subsidiary, Suven Neurosciences, Inc., USA, focused on clinical development activities of Suven molecules from phase 2, Proof-of-Concept (POC) studies. The Company is in the business of Contract Research And Manufacturing Services (CRAMS), catering to the needs of global life science industry and fine chemical majors. Suven's CRAMS provide innovative process research and development, supplies to clinical trials, rapid response pilot scale manufacture, dedicated commercial manufacturing on an exclusive basis. The services include Custom Synthesis, Process R&D, Scale Up and Contract Manufacturing of intermediates, APIs and formulations. Suven Life Sciences has graduated from contract research to Collaborative Research transitioning from project-based transactions into relationship-based business. In March 1995, SPL came out with a public issue of 9.8 lac equity shares at a premium of Rs 40 aggregating Rs 4.9 cr to part-finance the company's project for the manufacture of bulk drugs and drug intermediates and meet long-term working capital requirements totalling to Rs 6.43 cr. During 1999-2000, the company acquired a small pilot plant in Jeedimetla Industrial Estate, Hyderabad. During 2000-01, the company has registered a most remarkable record. The total sales of the company during 2000-01 have registered a growth of 71% over the previous year. The Profit After Tax (PAT) has also registered a growth of 325% over the previous year. During the financial year ended 31 March 2014, Suven's Drug discovery portfolio has expanded into several new therapeutic areas such as Major Depressive Disorder (MDD), Obesity and Pain through Neuronal Nicotinic Receptor modulators. In addition, D-4010 and G3031 are undergoing regulatory toxicological studies in preparation for them being moving into Phase 1 clinical trial during 2014-15. During the year 2014, Suven has made significant inroads into drug discovery with a specialization on CNS-based programmes targeting unmet medical needs. The Company enjoys a unique position in the India (and Asia) as one of the prominent company with technologies under central nervous system (CNS). It has funded drug discovery for nine years resulting in a robust pipeline of 14 molecules at various stages of development. Suven's discovery assets address niche therapeutic areas like cognition, depression, obesity and pain management. In FY14, the Company filed one ANDA with the USFDA authorities for Malathion lotion, a head-lice product with sales potential estimated at US$35 million. In 2013-14, it granted the exclusive license to Taro Pharmaceuticals to market the product in the US, Canada and Mexico, which is expected to generate revenues and royalty in 2014-15. During FY2015, Suven's lead clinical candidate SUVN-502 has successfully completed Phase 1b clinical trial thus paving the way for the co-pound to move into Proof of Concept (PoC) Phase 2a study. In addition to above compounds, SUVN D-4010 is in its final stages of completing regulatory toxicological studies which will enable it to move into Phase 1 clinical trial in USA. During the FY2015, the Company has issued and allotted 104,53,690 equity shares of Re 1/- each at a premium of Rs 190.32 per share by way of QIP Issue in accordance with the SEBI ICDR guidelines. During FY15, the Company's main focus stayed on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets. During FY15, the Company added two new clients to its CRAMS business. It commenced operations at its Vishakhapatnam unit and shifted the manufacturing intermediates for a specialty chemical product to this unit. The shift not only optimized capacities at its CRAMS facilities but also made the CRAMS operations more efficient. During FY2017, the company has spent Rs. 6973 lakhs on innovative R&D in CNS therapies accounting for 13% on sales. Its focus remained on discovering, developing and commercializing novel pharmaceutical products, which are first in class CNS therapies through use of GPCR targets. During FY 2017, the Company has invested a sum of Rs 6501 lakhs in Suven Neurosciences Inc., a wholly owned subsidiary, for its business purpose. In FY2018, the company has spent Rs 6,390 lakhs on innovative R&D in CNS therapies accounting for 10% on sales. The Company invested a sum of Rs.13,636 lakhs in Suven Neurosciences, Inc., for its business purpose. The Company acquired entire share capital of Rs.1 lakh in Suven Pharmaceuticals Limited identified as Resulting Company for the purpose of Scheme of Arrangement (Demerger) and as of 31st March, 2019 no investments were made in newly formed Suven Pharma, Inc. in USA. During the FY 2018-2019, Suven Pharmaceuticals Limited in India and Suven Pharma, Inc., in USA became the subsidiary companies. In 2018-19, the Company completed the Clinical Trial (Phase II) of the lead molecule SUVN-502, Masupirdine. In 2019-20, the Contract Research and Manufacturing Services (CRAMS) Undertaking of the Company was demerged to its wholly owned subsidiary, Suven Pharmaceuticals Limited as a going concern through a Scheme of Arrangement effective from 1st October, 2018.
Suven Life Sciences to convene AGM
Suven Life Sciences announced that the 35th Annual General Meeting(AGM) of the company wil...
Read more
07 May 202412:58
Suven Life Sciences to announce Quarterly Result
Suven Life Sciences will hold a meeting of the Board of Directors of the Company on 6 May ...
Read more
29 Apr 202419:07
Suven Life Sciences to hold board meeting
Suven Life Sciences will hold a meeting of the Board of Directors of the Company on 30 Jan...
Read more
24 Jan 202413:53
Suven Life Sciences schedules board meeting
Suven Life Sciences will hold a meeting of the Board of Directors of the Company on 4 Nove...
Read more
30 Oct 202316:22
Suven Life Sciences announces board meeting date
Suven Life Sciences will hold a meeting of the Board of Directors of the Company on 8 Augu...
Read more
02 Aug 202316:49
Suven Life Sciences AGM scheduled
Suven Life Sciences announced that the 34th Annual General Meeting (AGM) of the company wi...
Read more
10 May 202312:27
FAQs for PE of Suven Life Sciences Ltd
What is Suven Life Sciences Ltd current share price?
What is Suven Life Sciences Ltd's market cap?
What are Suven Life Sciences Ltd's total net assets?
Is Suven Life Sciences Ltd making a profit or loss?
Unlimited trading at just
Rs. 199